Today, the FDA issued a draft guidance titled Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection (here).  The pre-publication Federal Register notice (here) indicates that the stated purpose of the guidance “is to assist manufacturers who choose to respond to FDA when they receive an FDA Form 483 Inspectional Observations (FDA 483) at the conclusion of a drug inspection to assess conformity with current good manufacturing practice (CGMP) requirements”  The FDA notes that firms’ responses are often either incomplete or lack clarity or specific data to support the actions that the firms have taken to resolve the Agency’s inspectional observations.

The guidance applies to drug and biologic products, including combinations products, regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary Medicine (CVM).

“The guidance provides recommendations that manufacturing establishments should follow to prepare concise, factual, and effective corrective action responses to observations that FDA documents on an FDA 483 during an inspection.”  The FDA also notes that “[p]oor quality or incomplete responses make it difficult for FDA to ascertain what the establishment has corrected since the inspection and to evaluate remediation activities.  This difficulty has ramifications for FDA’s ability to help firms achieve voluntary compliance, take appropriate enforcement action, and most importantly, minimize exposing patients and the public to risks.”

The guidance outlines how responses should be put together as well as the items and data that firms should include in their responses.  The FDA addresses the following topics:

  • Submitting a Response to a FDA 483
    • Response Format and Content
    • Interim Reporting
    • Where to Respond
    • Response Submission Timeframe
  • Recommendations for Addressing FDA 483 Observations
    • Understanding and Assessing the Observations
    • Management Responsibility
    • Develop an Investigation Plan and Conduct an Investigation
    • Develop and Implement a CAPA Plan
    • Evaluate CAPA Effectiveness

And, lastly, there is a section on resolving scientific disputes with FDA 483 observations.

If you need assistance in responding to FDA Form  483 observations, please contact us at LCS@lachmanconsultants.com.  Lachman has been extremely successful in assisting firms with compliance issues and helping firms proactively maintain cGMP compliance status.  Remember, it cost more to get out of a compliance problem than it does to avoid getting into one.